{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.07","value":"46.34"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"CYCLE 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.80"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"CYCLE 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"CYCLE 6"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.90"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"CYCLE 9"},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"CYCLE 10"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.60"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"CYCLE 11"},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.60"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"CYCLE 12"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with RRMM received belantamab mafodotin as dose of 2.5mg/kg via IV infusion on Day 1 of every 21-day cycle (Q3W) maximum up to disease progression. Bortezomib was administered subcutaneously (SC) as 1.3 mg/meter\\^2 (m\\^2) on Day 1, Day 4, Day 8, and Day 11 of every 21-day cycle maximum up to 8 cycles. Dexamethasone was administered orally as dose of 20 mg on Day 1, Day 2, Day 4, Day 5, Day 8, Day 9, Day 11, and Day 12 of every 21-day cycle maximum up to 8 cycles.","id":"OG000","title":"Main Study - Part 2: ArmA-Belantamab Mafodotin 2.5 mg/kg + Bortezomib and Dexamethasone (Bor/Dex)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic population. Only those participants with data available at specified time points have been analyzed.","reportingStatus":"POSTED","timeFrame":"Cycle 1, Cycle 4, Cycle 6, Cycle 9, Cycle 10, Cycle 11 and Cycle 12","title":"Part 2 Arm A: C-EOI Following Repeat Dose Administration of Belantamab Mafodotin (ADC)","type":"SECONDARY","unitOfMeasure":"ug/mL"}